| Name | Title | Contact Details |
|---|
Rural/Metro Corporation is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Rural/Metro Corporation is based in Scottsdale, AZ. You can find more information on Rural/Metro Corporation at www.rmetro.com
LEARN Behavioral is a national organization that specializes in providing tailored treatment programs for children and young adults with autism spectrum disorder (ASD). We use contemporary applied behavior analysis (ABA) therapy that is based on the un...
IndiPharm is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since its beginning in 2007 as a technical staffing and business solutions group in Annapolis, Md., Syndicus has evolved into a highly respected technical staffing and consulting solutions group that provides talent and solutions for three focus areas: Health Information Technology, Life Sciences Solutions and Technology Services. We pride ourselves in partnering with top subject matter experts who ensure candidates, consultants and solutions meet clients' specialized needs. In 2012, Syndicus achieved both a full national accreditation with the Management Services Organization Accreditation Program (MSOAP) from the Electronic Healthcare Network Accreditation Commission (EHNAC) and the MSO State Designation from the Maryland Health Care Commission (MHCC). The two certifications enable Syndicus and its electronic health records (EHR) hosted solutions provider eCast Corporation to continue working with Maryland healthcare providers on EHR adoption efforts – and subsequent achievement of Meaningful Use.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.